• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Seek Safety in Two Health Care Stocks

United Therapeutics and PharMerica have strong insider buying and should perform in a turbulent market.
By BRET JENSEN
Jun 26, 2012 | 01:00 PM EDT
Stocks quotes in this article: UTHR, PMC

Monday provided the start to another rocky week in the market. Investors were awaiting the latest news from Europe as well as the Supreme Court decision on the Obama administration's health care overhaul. The market received very little news on either. We should have clarity on the court's decision by Thursday, as Europe looks to be a soap opera that is going to run for some time. Regardless of the ultimate outcome for Obamacare, the healthcare sector is a good defensive area for investors to hide until the market gets better news from Europe, as well as clarity on the direction of worldwide growth.

Here are two cheap health care stocks that should do fine even in a turbulent environment and have had strong recent insider buying.

United Therapeutics (UTHR) is a biotechnology company that develops therapeutic products for patients with chronic and life-threatening diseases in the U.S. and internationally.

Four reasons UTHR looks like a buy at $47 a share:

  • A director picked up more than $1.5 million in new shares earlier this month. The company also has a solid balance sheet with net cash on the books.
  • The stock is selling at the very bottom of its five-year valuation range based on price/earnings, price/sales, price/book and price/cash flow ratios.
  • The market is deeply discounting the company's growth prospects. UTHR grew revenues at a better than 30% annual clip over the past five years. Even though growth is slowing, analysts still expect sales growth in the teens for both 2012 and 2013. The stock has a minuscule five-year projected price/earnings/growth ratio of 0.45, as well.
  • United Therapeutics is selling for 9.5x forward earnings, a steep discount to its five-year average (29.2). It also increased its operating cash flow 250% from 2009 to 2011 and sells for around 10x operating cash flow.

PharMerica (PMC) provides pharmacy services to health care facilities and hospitals in 44 states.

Four reasons PMC offers value at just over $10.50 a share:

  • The stock is very cheap at just 75% of book value and 15% of annual sales.
  • Three insiders stepped up and bought more than $500,000 in new shares in early June. Analysts also like the stock at these levels. The seven analysts that cover the stock have a median price target of $15 a share.
  • The company has consistently beaten earnings estimates. It has served up a beat for the last six quarters and the average beat over consensus during the last four quarters has averaged an impressive 40%.
  • PMC sells for less than 8.5x forward earnings, a deep discount to its five-year average (17.9).
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long UTHR.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Here's the Level to Zero In on for UnitedHealth Group

Bruce Kamich
Jun 13, 2022 7:29 AM EDT

Shares of the diversified healthcare company have held up fairly well despite the decline in the broader market but soon could be put to the test.

3 Dividend-Paying Healthcare Stocks That Age Well

Bob Ciura
Jun 5, 2022 12:30 PM EDT

Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login